Clinical trial · Observational
Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This was a national survey of physicians. Per the protocol, they were only allowed to be contacted twice and they received less surveys back than anticipated.
Summary
Brief summary (as posted)
In order to formulate strategies to improve adherence to best practice guidelines, as well as utilization of novel therapies, investigators must understand current practice patterns surrounding tumor genetic testing in endometrial cancer. The aim is to survey a representative sample of gynecologic oncologists who belong to the society of gynecologic oncology, via an email survey, to better understand current practices surrounding tumor genetic testing as well as determine if there have been any changes to practice since the publication of recent trials on the use of immune-checkpoint inhibitors in endometrial cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surveys | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Gynecologic Oncologists
- description
- Gynecologic Oncologists and gynecologic oncology fellows-in-training from around the world, who are members of the Society of Gynecologic Oncology (SGO).
- interventionNames
- Other: Surveys
Primary outcomes (1)
- measure
- Percentage of providers reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients
- timeFrame
- 4 months
- description
- The primary outcome is to estimate the percentage of providers who report the use of different tumor testing strategies. Investigators will calculate the frequencies of responses to each testing strategy and then compare the percentage of physicians who choose different strategies, using a chi-square or Fisher's exact test.
Secondary outcomes (3)
- measure
- Frequency of providers using different strategies of informed consent in tumor genetic testing in endometrial cancer
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Member of the Society of Gynecologic Oncology * Gynecologic Oncologist or Gynecologic Oncology Fellow-in-Training
References
Publications (0)
Data not yet available